Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

Long-Term Data for Kite's Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Foster City , California , Santa Monica , American , Meaghan Smith , Jacquie Ross , Frank Neumann , Anna Padula , Julioc Chavez , Gilead Company Nasdaq , Kite Global Head Of Clinical Development , American Society Of Hematology , Linkedin , Gilead Sciences Inc , Gilead Sciences , Moffitt Cancer Center , Exchange Commission , International Prognostic Index , Gilead Company , First Ever Prospective Phase , Cell Therapy , Patients Treated , Complete Response Rate , Three Year Estimate , Overall Survival , High Risk Largeb Cell Lymphoma , Patients Typically Face Poor Prognoses , Conventional Treatment , Median Overall Survival Under , American Society , Annual Meeting , Moffitt Cancer , Confidence Interval , Global Head , Lugano Classification , Release Syndrome , Risk Evaluation , Mitigation Strategy , Private Securities Litigation Reform Act , Quarterly Report , Gilead Media , Kite Media ,